European Parliament SANT committee meets on pharma, rare diseases, Biotech Act

Process in Brief

The committee held debates and consideration of amendments on the EU cardiovascular diseases strategy and the European Competitiveness Fund, received a report-back on negotiations for the Critical Medicines Act, and conducted votes to adopt pilot projects and preparatory actions for the 2027 Union budget as well as on the provisional agreements for the pharmaceutical package. It also hosted a workshop on rare diseases and an exchange of views on excellence in health science, and held a joint SANT‑ITRE session on the European Biotech Act.

What Is at Stake

The agenda covered regulation and supervision of medicinal products for human use and governing rules for the European Medicines Agency, critical medicines and pharmaceutical preparedness, EU strategies for cardiovascular and rare diseases, health research priorities including exposome science, and the regulatory framework for biotechnology. Presentations and exchanges involved invited experts, rapporteurs, SANT members and a Commission presentation on the Biotech Act.

Timeline

The committee's next meeting is scheduled for 14 April 2026 in Brussels.

Sources

Official Documents

Latest EU trade developments

Similar policy actions

Language